Latest Gene Therapy News

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

Barramundi Limited’s May update reveals a 2.3% adjusted NAV decline, weighed down by CSL’s earnings downgrade and Brambles’ operational setbacks, despite positive contributions from Xero and Credit Corp.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

Vitrafy Life Sciences completed Phase II of its U.S. Military platelet cryopreservation study with strong results for a simplified no-wash process, accelerating commercial interest and progressing FDA device registration despite manufacturing delays.

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.

Cryosite Limited reported a robust half-year with revenue up 25% and net profit rising 36%, driven by strong demand in temperature-controlled logistics and a strategic warehouse acquisition that doubles its storage capacity.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.